Nova Mentis Life Science (Nova Mentis Life Science) Momentum Rank : 0 (As of Jun. 08, 2024)

View and export this data going back to 2013. Start your Free Trial

What is Nova Mentis Life Science Momentum Rank?

Nova Mentis Life Science has the Momentum Rank of 0.

For Momentum Rank, we considered the residual momentum concept that was widely studied by Blitz and his colleagues as well as by Nobel Prize laureates Fama and French. However, we did not find any significant differences in the performances of stocks with different ranks of residual momentum. Therefore, we use traditional momentum instead.

Momentum Rank is determined using the standardized momentum ratio and other momentum indicators. The standardized momentum ratio is the average of the performances from 12 months ago to 1 month ago and 6 months ago to 1 month ago, divided by the beta of the stock over the past 12 months. To calculate the momentum ratio today, we would use the average of the two performance numbers.

For momentum, we found that stock price performance does not have a monotonic correlation with the momentum ratio. The stocks with the highest momentum ratios perform worse than those at about the 70th percentile. Therefore, for the momentum rank, we ranked the stocks at about the 70th percentile of the momentum ratio as the highest at 10.

Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.

Nova Mentis Life Science Momentum Rank Related Terms

Thank you for viewing the detailed overview of Nova Mentis Life Science's Momentum Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

Nova Mentis Life Science (Nova Mentis Life Science) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nova Mentis Life Science Corp (OTCPK:NMLSF) » Definitions » Momentum Rank

Comparable Companies

Traded in Other Exchanges

HN3Q:Germany NOVA:Canada

Address

700-838 West Hastings Street, Vancouver, BC, CAN, V6C 0A6

Website

https://www.novamentis.ca

Nova Mentis Life Science Corp is a Canadian-based biotechnology company. It is engaged in developing diagnostics and psilocybin-based therapeutics for neuroinflammatory disorders. Nova uses psilocybin in the treatment of Fragile X Syndrome (FXS). The company's goal is to diagnose and treat debilitating chronic conditions that have unmet medical needs such as autism spectrum disorder (ASD) and FXS. It has one industry segment, being research and development of psilocybin, and in one geographic area, which is Canada.